{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "BCG",
      "Heterologous",
      "Influenza vaccine",
      "Innate immunity",
      "Non-specific immunity",
      "Trained immunity",
      "Vaccination",
      "Vaccine"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34058986",
  "DateCompleted": {
    "Year": "2021",
    "Month": "06",
    "Day": "07"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "01"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "05",
        "Day": "31"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "54",
      "10.1186/s10020-021-00317-z"
    ],
    "Journal": {
      "ISSN": "1528-3658",
      "JournalIssue": {
        "Volume": "27",
        "Issue": "1",
        "PubDate": {
          "Year": "2021",
          "Month": "May",
          "Day": "31"
        }
      },
      "Title": "Molecular medicine (Cambridge, Mass.)",
      "ISOAbbreviation": "Mol Med"
    },
    "ArticleTitle": "Heterologous vaccine interventions: boosting immunity against future pandemics.",
    "Pagination": {
      "StartPage": "54",
      "MedlinePgn": "54"
    },
    "Abstract": {
      "AbstractText": [
        "While vaccines traditionally have been designed and used for protection against infection or disease caused by one specific pathogen, there are known off-target effects from vaccines that can impact infection from unrelated pathogens. The best-known non-specific effects from an unrelated or heterologous vaccine are from the use of the Bacillus Calmette-Gu\u00e9rin (BCG) vaccine, mediated partly through trained immunity. Other vaccines have similar heterologous effects. This review covers molecular mechanisms behind the heterologous effects, and the potential use of heterologous vaccination in the current COVID-19 pandemic. We then discuss novel pandemic response strategies based on rapidly deployed, widespread heterologous vaccination to boost population-level immunity for initial, partial protection against infection and/or clinical disease, while specific vaccines are developed."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0003-1362-6881"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, Belfer Research Building, Room 530, 413 E. 69th street, New York, NY, 10065, USA. dma4001@med.cornell.edu."
          }
        ],
        "LastName": "Mar\u00edn-Hern\u00e1ndez",
        "ForeName": "Daniela",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, Belfer Research Building, Room 530, 413 E. 69th street, New York, NY, 10065, USA."
          }
        ],
        "LastName": "Nixon",
        "ForeName": "Douglas F",
        "Initials": "DF"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Population Health Sciences, Weill Cornell Medicine, 402 E. 67th Street, New York, NY, 10065, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Cornell Institute for Disease and Disaster Preparedness, Weill Cornell Medicine, 402 E. 67th Street, New York, NY, 10065, USA."
          }
        ],
        "LastName": "Hupert",
        "ForeName": "Nathaniel",
        "Initials": "N"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Mol Med",
    "NlmUniqueID": "9501023",
    "ISSNLinking": "1076-1551"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "BCG Vaccine"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "immunology",
        "therapeutic use"
      ],
      "DescriptorName": "BCG Vaccine"
    },
    {
      "QualifierName": [
        "immunology",
        "prevention & control",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Immunity, Heterologous"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "immunology",
        "therapeutic use"
      ],
      "DescriptorName": "Vaccines"
    }
  ],
  "CoiStatement": "The authors declare that they have no competing interests."
}